 Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a peer-reviewed article published in Clinical Cancer Research Clin Cancer Res June 30 2020 DOI:10.11581078-0432.CCR-19-4092 reported findings that Moleculins STAT3 inhibitor, WP1066, used in combination with traditional whole brain radiation therapy WBRT resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors. 